RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE

By continuing to use this site, you consent to our use of cookies. Learn more in our privacy policy.

Close

Accept

Connect. Hydrolyze. Absorb.

Fat malabsorption can keep your body from breaking down fats from nutrition which are important for proper health. If you need help breaking down fats from enteral tube feeding formula, your doctor may prescribe RELiZORB.

RELiZORB is a digestive enzyme cartridge that contains iLipase®, which is the enzyme lipase attached to small white bead carriers. RELiZORB connects directly to your feeding tube and as the formula passes through, it makes contact with the iLipase, hydrolyzing (or breaking down) the fat in formula to an absorbable form (called fatty acids and monoglycerides), all before entering your body.

See how RELiZORB works

iLipase is made up of the digestive enzyme lipase attached to small polymeric microbead carriers and is stored within the RELiZORB cartridge which connects directly to your feeding tube.

See how RELiZORB works

Trenton's Story

See how RELiZORB is helping a 17-year old student and lacrosse player living with cystic fibrosis

See how RELiZORB is helping a 17-year old student and lacrosse player living with cystic fibrosis

See more patient stories

The symptoms and consequences of fat malabsorption

Fats play an important role in nutrition and certain fats are critical to growth and development. If your body has trouble breaking down these fats, symptoms can develop and will often get worse over time.1

When your body doesn’t properly break down fats it can lead to GI symptoms including:2,3

  • Diarrhea
  • Steatorrhea
  • Abdominal pain and discomfort
  • Nausea
  • Bloating and gas
  • Weight loss
  • Fatigue

Overall short- and long-term health consequences are multisystemic and varied:1,4-7

  • Malnutrition
  • Micronutrient deficiencies
    (including fat-soluble vitamins)
  • Weight loss or inability to gain weight
  • Pediatric developmental delays
  • Death

See more about fat malabsorption

References
  1. Sankararaman S, Schindler T, and Sferra TJ. Management of Exocrine Pancreatic Insufficiency in Children. Nutrition in Clinical Practice. 2019;34(1):S27-S42.
  2. Blaauw R. Malabsorption: causes, consequences, diagnosis and treatment. S Afr J Clin Nutr. 2011;24(3):125-127.
  3. Alkaade S, Vareedayah AA. A Primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. Am J Manag Care. 2017;23(supp 12):S203-S209.
  4. Mayo Clinic Website. Cystic fibrosis: symptoms and causes. http://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/symptoms-causes/dxc-20211893. Accessed October 16, 2017.
  5. Kalnins D, Wilschanski M. Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies. Drug Des Devel Ther. 2012;6:151-161.
  6. Dominguez-Munoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011;26(2):12-16.
  7. Turck D, Braegger CP, Colombo C, Declercq D, Morton A, Pancheva R, Robberecht E, Stern M, Strandvik B, Wolfe S, Schneider SM, Wilschanski M. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clinical Nutrition. 2016;35(3):557-577.